TNXP · Tonix Pharmaceuticals Holding Corp. · Webcasts, Transcripts & Audio
$5.17
+0.04 (+0.78%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$88.67M
Shares
17.15M
Volume · Oct 23
754.75K
Avg daily vol (3M)
638.76K
Tonix Pharmaceuticals Holding Corp. Webcasts
Earnings calls, investor updates, investor days and conferences for Tonix Pharmaceuticals Holding Corp. (TNXP), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-21
Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-10
Tonix Pharmaceuticals Holding Corp. (TNXP) September 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
Tonix Pharmaceuticals Holding Corp. (TNXP) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-10
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Confident tone
Tonmaya launch performance
Competitor landscape (Pfizer VALOR)
TNX-4800 Lyme disease prevention
Revenue
$13.54M
▲ 577.9% YoY Diluted EPS
$-2.44
Gross margin
94.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-13
Tonix Pharmaceuticals Holding Corp. (TNXP) Q4 2025 Earnings Call
Revenue
$5.39M*
▲ 108.8% YoY Gross margin
80.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Showing 1–5 of 5 webcasts
Key facts
CIK
1430306
CUSIP
890260839
13F (30d)
16 filings
16 filers
Visit website
Investor relations